Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study
Identifieur interne : 001E14 ( PascalFrancis/Corpus ); précédent : 001E13; suivant : 001E15Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study
Auteurs : Albert F. G. Leentjens ; Kathy Dujardin ; Laura Marsh ; Pablo Martinez-Martin ; Irene H. Richard ; Sergio E. StarksteinSource :
- Movement disorders [ 0885-3185 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 11-0211297 INIST |
---|---|
ET : | Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study |
AU : | LEENTJENS (Albert F. G.); DUJARDIN (Kathy); MARSH (Laura); MARTINEZ-MARTIN (Pablo); RICHARD (Irene H.); STARKSTEIN (Sergio E.) |
AF : | Department of Psychiatry, Maastricht University Medical Center/Maastricht/Pays-Bas (1 aut.); Neurology and Movement Disorders Unit, Lille University Hospital/Lille/France (2 aut.); Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine/Baltimore/Etats-Unis (3 aut.); Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health/Madrid/Espagne (4 aut.); Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry/Rochester/Etats-Unis (5 aut.); School of Psychiatry, University of Western Australia and Fremantle Hospital/Fremantle/Australie (6 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 3; Pp. 484-492; Bibl. 29 ref. |
LA : | Anglais |
EA : | Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD. |
CC : | 002B17; 002B17G |
FD : | Trouble anxieux; Maladie de Parkinson; Angoisse anxiété; Etat dépressif; Pathologie du système nerveux; Symptomatologie; Etude transversale; Echelle d'évaluation; Inventaire |
FG : | Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Affect affectivité; Trouble de l'humeur |
ED : | Anxiety disorder; Parkinson disease; Anxiety; Depression; Nervous system diseases; Symptomatology; Cross sectional study; Evaluation scale; Inventory |
EG : | Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Affect affectivity; Mood disorder |
SD : | Trastorno ansiedad; Parkinson enfermedad; Angustia ansiedad; Estado depresivo; Sistema nervioso patología; Sintomatología; Estudio transversal; Escala evaluación; Inventario |
LO : | INIST-20953.354000190875360170 |
ID : | 11-0211297 |
Links to Exploration step
Pascal:11-0211297Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study</title>
<author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Medical Center</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="04"><s1>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation><inist:fA14 i1="06"><s1>School of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0211297</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0211297 INIST</idno>
<idno type="RBID">Pascal:11-0211297</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E14</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study</title>
<author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Medical Center</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="04"><s1>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation><inist:fA14 i1="06"><s1>School of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety</term>
<term>Anxiety disorder</term>
<term>Cross sectional study</term>
<term>Depression</term>
<term>Evaluation scale</term>
<term>Inventory</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Symptomatology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Trouble anxieux</term>
<term>Maladie de Parkinson</term>
<term>Angoisse anxiété</term>
<term>Etat dépressif</term>
<term>Pathologie du système nerveux</term>
<term>Symptomatologie</term>
<term>Etude transversale</term>
<term>Echelle d'évaluation</term>
<term>Inventaire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LEENTJENS (Albert F. G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DUJARDIN (Kathy)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARSH (Laura)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RICHARD (Irene H.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STARKSTEIN (Sergio E.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Medical Center</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>School of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>484-492</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000190875360170</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>29 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0211297</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Trouble anxieux</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Anxiety disorder</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Trastorno ansiedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Angoisse anxiété</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Anxiety</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Angustia ansiedad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Depression</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Symptomatologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Symptomatology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Sintomatología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etude transversale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cross sectional study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estudio transversal</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Echelle d'évaluation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Evaluation scale</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Escala evaluación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Inventaire</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Inventory</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inventario</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Affect affectivité</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Affect affectivity</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Afecto afectividad</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>43</s5>
</fC07>
<fN21><s1>143</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0211297 INIST</NO>
<ET>Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study</ET>
<AU>LEENTJENS (Albert F. G.); DUJARDIN (Kathy); MARSH (Laura); MARTINEZ-MARTIN (Pablo); RICHARD (Irene H.); STARKSTEIN (Sergio E.)</AU>
<AF>Department of Psychiatry, Maastricht University Medical Center/Maastricht/Pays-Bas (1 aut.); Neurology and Movement Disorders Unit, Lille University Hospital/Lille/France (2 aut.); Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine/Baltimore/Etats-Unis (3 aut.); Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health/Madrid/Espagne (4 aut.); Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry/Rochester/Etats-Unis (5 aut.); School of Psychiatry, University of Western Australia and Fremantle Hospital/Fremantle/Australie (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 3; Pp. 484-492; Bibl. 29 ref.</SO>
<LA>Anglais</LA>
<EA>Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD.</EA>
<CC>002B17; 002B17G</CC>
<FD>Trouble anxieux; Maladie de Parkinson; Angoisse anxiété; Etat dépressif; Pathologie du système nerveux; Symptomatologie; Etude transversale; Echelle d'évaluation; Inventaire</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Affect affectivité; Trouble de l'humeur</FG>
<ED>Anxiety disorder; Parkinson disease; Anxiety; Depression; Nervous system diseases; Symptomatology; Cross sectional study; Evaluation scale; Inventory</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Affect affectivity; Mood disorder</EG>
<SD>Trastorno ansiedad; Parkinson enfermedad; Angustia ansiedad; Estado depresivo; Sistema nervioso patología; Sintomatología; Estudio transversal; Escala evaluación; Inventario</SD>
<LO>INIST-20953.354000190875360170</LO>
<ID>11-0211297</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E14 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001E14 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:11-0211297 |texte= Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |